

**Prescription Drug
Affordability Board
Advisory Group**

Minutes

Tuesday, December 10, 2024

Virtual Meeting

2:00 – 4:00 PM

Time	Agenda Topic	Key Decision / Notes
2:00pm	Welcome & Introductions	
	Discuss Advisory Group Lead	Jim Freeburg offered to act as the group lead
	Discuss Drug Selection Process	Kelly discussed the selection and weighting presentation with the group, and questions were brought up around: definition of specialty drug(we discussed how HCA chose to define it), if drug selections could be construed as arbitrary (we are using measures to create an ordered list, but there are other factors the board is allowed to consider), why there are multiple doses of the same drug on the list (we broke it out by NDA and how we define “drug”), having two top 25 lists (board members wanted it that way), and how prices may be misleading because they don’t include rebates (we are working off the data we have access to, and we will work to have more info on rebates in specific drug reviews)
	Discuss Drug Selection Recommendation Strategy (Advisory Group members each select 5 drugs to recommend to the Board)	The group members are to select 5 drugs each and send their responses and reasoning to Michael Neuenschwander by Dec 31. Their recommendations will then be forwarded to the PDAB for their review prior to the Jan PDAB meeting. Group recommendations will then be discussed, and have possible invitation for the group to speak to the board. Dharia declined to give any recommendations due to her position with industry.
	Set plan for next meeting	We will hold on future meetings until the board directs further work for the advisory group to do
4:00 p.m.	Adjourn	